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Abstract: High arsenic (As) levels in food and drinking water, or under some occupational conditions,
can precipitate chronic toxicity and in some cases cancer. Millions of people are exposed to
unacceptable amounts of As through drinking water and food. Highly exposed individuals may
develop acute, subacute, or chronic signs of poisoning, characterized by skin lesions, cardiovascular
symptoms, and in some cases, multi-organ failure. Inorganic arsenite(III) and organic arsenicals with
the general formula R-As2+ are bound tightly to thiol groups, particularly to vicinal dithiols such as
dihydrolipoic acid (DHLA), which together with some seleno-enzymes constitute vulnerable targets
for the toxic action of As. In addition, R-As2+-compounds have even higher affinity to selenol groups,
e.g., in thioredoxin reductase that also possesses a thiol group vicinal to the selenol. Inhibition of
this and other ROS scavenging seleno-enzymes explain the oxidative stress associated with arsenic
poisoning. The development of chelating agents, such as the dithiols BAL (dimercaptopropanol),
DMPS (dimercapto-propanesulfonate) and DMSA (dimercaptosuccinic acid), took advantage of the
fact that As had high affinity towards vicinal dithiols. Primary prevention by reducing exposure of
the millions of people exposed to unacceptable As levels should be the prioritized strategy. However,
in acute and subacute and even some cases with chronic As poisonings chelation treatment with
therapeutic dithiols, in particular DMPS appears promising as regards alleviation of symptoms. In
acute cases, initial treatment with BAL combined with DMPS should be considered.
Keywords: arsenic; drinking water; arsenic poisoning; lipoic acid; BAL; DMPS
1. Introduction
The element arsenic (As) belongs to Group 15 in the periodic system. Additionally, it is chemically
classified as a metalloid. It occurs in many minerals in the Earth’s crust, often together with other metals
and sulfur. In recent years China, together with Russia and Morocco, have been the top producers of
As [1]. However, nowadays most As refinement operations have been phased out in the USA and
Europe, due to environmental concerns.
Until recently, several compounds of As were used as pesticides and herbicides [2]. Due to its
antifungal properties, chromated copper arsenate was used to treat and preserve wood. However,
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the use of this As compound in consumer products was banned in 2004 in the USA as well as in the
European Union due to mounting evidence of As toxicity [3]. Spraying of fruit trees with methylated
arsenates, as well as with other arsenicals, have also been extensively used until recently, due to their
insecticidal properties. However, the use of arsenicals in agricultural activities has been phasing out
in the Western world from about 2013. Nowadays, the US Agency for Toxic Substances and Disease
Registry places As as number one on their Priority List of Hazardous Substances [4]. The International
Agency for Research on Cancer (IARC) classifies arsenic (As) and inorganic arsenic (iAs) compounds
in Group 1, carcinogenic to humans [5].
In their hazard assessment, The Joint FAO/WHO Expert Committee on Food Additives (JECFA) [6]
modeled dose-response data from recent studies on lung and urinary tract cancer and established a
benchmark dose for 0.5% elevated lung cancer incidence above background, with 95% confidence limit,
for a daily dose between 3.0 and 5.0 µg As/kg body weight (mainly iAs). They selected the lowest dose
of 3.0 µg As/kg body weight per day as a risk assessment reference point. In different countries in
Europe and Asia as well as in the USA, it has been reported that mean dietary iAs exposure ranges
from 0.1 to 3.0 µg As/kg body weight per day, illustrating that As in food and drinking water may
constitute a public health concern [7]. In 2014, the WHO held an advisory conference to confirm limits
for rice of 200–300 µg/kg [8].
In 2006, the US Environmental Protection Agency (EPA) set 10 µg/L as the maximum allowed
concentration of As in drinking water [9]. The Occupational Safety and Health Administration has set
a permissible exposure limit (PEL) as a time-weighted average (TWA) of 0.01 mg/m3. The National
Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) of
0.002 mg As/m3 for 15-min constant exposure [10].
The biochemistry of As is similar to other elements found in Group 15 of the periodic table, in
particular phosphorous, and to some extent also nitrogen. Thus, arsenate (AsO43−), the dominating
As species in seawater, occurs together with phosphate (PO43−), and these two compounds are
indistinguishable to marine algae, explaining their high AsO43− uptake. During changing conditions of
salinity, aquatic organisms synthesize the nitrogen-containing compound glycine betaine to maintain
the osmotic balance. However, due to structural mimicry As can replace nitrogen in this synthesis [11],
which may explain the high arsenobetaine concentrations in the marine nutrition chain.
The abundant occurrence of organoarsenicals, in nature as in the laboratory, is a result of the high
electronegativity of As, viz. 2.18 on the Pauling scale, which is a little lower than that of carbon (2.55),
sulfur (2.58) and selenium (2.55). Consequently, As has a high tendency, compared with other metals,
to be involved in covalent bonding to carbon, as well as to sulfur and selenium [12].
Before the developments of modern antibiotics and cytostatic agents, different organic as well as
iAs compounds were used as pharmaceuticals, for instance, Salvarsan (arsphenamine) for syphilis [13]
and arsenic trioxide for cancer [14]. In treatment of psoriasis, the As-containing Fowler’s solution was
recommended, but later it was found in a dose-related manner to increase the risk of skin cancer [15],
Still. As(III) trioxide is approved as a treatment in cases of acute promyelocytic leukemia, but only
when conventional regimens are not effective [16].
Arsenic has four oxidation states, i.e., −3, 0, +3, and +5. Under aerobic conditions, the latter is the
dominant oxidation state [17]. This review focuses on the +3 and +5 oxidation states of As. Today both
of these series of compounds have worldwide toxicological relevance, which motivated to elaborate
the present overview. In the present work we aim to give a narrative review of environmental sources
of As exposure, health hazards, molecular targets of toxicity and therapeutic measures in acute and
chronic As toxicity.
Literature published after the year 2000 has been searched in Pubmed, Medline and Google
scholar by making use of the search keyword As combined with a second keyword, either environment,
toxicity, targets or therapeutics. In addition, references to some earlier papers are included to illustrate
historical perspectives. The article is focused on inorganic arsenic compounds (iAs), and the symbol
As refers to the element arsenic not further specified.
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2. Sources of Exposure
2.1. Arsenic in Drinking Water
Worldwide an estimated 200 million people are exposed to As in drinking water above the WHO
recommended guideline of 10 µg/L [18]. The majority lives in southern Asia, but also populations
living in other areas are affected. Arsenic in ground water and drinking water occurs as iAs, but is in
chemical analyses usually determined as total As.
The groundwater levels of As has caused significant exposure and frequent As poisoning, as is
reported i.a. from West Bengal and Bangladesh (Figure 1) [19].
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More than 50 million people in these regions drink groundwater containing As levels above 50
µg/L [21]. It is known that As occurring in sediments in some areas of the world can be released into
the groundwater. Southeast Asian districts and countries, including Cambodia, Vietnam, China, and
Taiwan have groundwater with high As content due to their geological environments [22].
In the USA, groundwater in the southwest regions frequently contains significant amounts of As
(Figure 1). Thus, it is estimated that the As values in about 16% of wells in New Mexico exceed 10
µg/L, most of this As contamination being focused in the Middle Rio Grande Basin [23,24]. In Arizona,
values in the range 10–210 µg/L have been reported for well water [25].
High levels of As in ground and surface water related to mining activities have been reported
from Peru [26]. In a district in Northern Chile the As content in drinking water exceeded 100 µg/L
until 1979 when an As-removal plant was built. In fact, after 2004 levels of As in drinking water in the
same region had dropped to about 10 µg/L [27]. At different sampling sites in Northern Argentina,
the measured concentrations of As in drinking water were as high as about 2000 µg As/L [28]. These
high levels in Chile and Argentina are explained by geological characteristics related to the Andes
mountain range.
Recent studies conducted in Serbia, showed substantially elevated levels of As when compared
with the limit of 10 µg/L. Determined levels of As in investigated water samples from the public
water supply system of the Northern region of Serbia were more than ten-fold higher than the
recommendation and even reached levels above 300 µg/L [29]. These findings can be explained by
geological characteristics of the Northern region of Serbia belonging to the Pannonian Basin (Hungary,
Romania, Croatia and Serbia) known to contain elevated naturally occurring As. It has been estimated
that nearly 500,000 people are exposed to levels above the recommended limit, making this region the
largest affected area in Europe [30].
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2.2. Arsenic in Food
For individuals who are neither occupationally exposed to As nor via drinking water, the most
important source of As is food [31]. Among food of earthbound origin, some cereals, such as rice have
As concentrations which are sometimes as high as 0.4 mg/kg dry weight [6]. The main As species in
rice and other plants irrigated with As-containing water or grown on As rich soil is iAs [7,32].
In contrast to terrestrial organisms that mainly contain inorganic As, most of As in marine
organisms are organoarsenicals. In particular, in organisms from the upper part of the marine food
chain, arsenobetaine is the prevalent arsenical compound [33]. However, in marine algae, arsenosugars
occur as the most significant arsenicals [34], and these are prevalent also in shellfish [33]. Arsenolipids,
also synthesized in algae in place of phosphate, occur in the lipid phase of marine organisms and are
present in various types of seafood, including cod liver oil and tuna [35,36]. Marine fish, as well as other
kinds of marine seafood, contain As concentrations up to 100 mg As/kg [32]. While in marine organisms
arsenobetaine is a more common arsenical [33], fresh-water organisms also contain As as arsenobetaine,
but in much lower concentrations. Lower-ranking organisms contain a larger fraction bound to sugars
and in various other low molecular weight compounds including sulfur-containing molecules.
2.3. Occupational Exposure
Occupational exposure to As compounds is another important source of exposure. Occupational
exposure in some cases can even lead to As poisoning, especially in industries that are using inorganic
As, or in workers using other toxic arsenicals. These include wood preservation, vineyard spraying,
nonferrous metal alloys, glass production, and production of electronic semiconductors [37]. Inorganic
As (iAs) is also emitted from the smelter industries, such as As or copper smelters, resulting in both
occupational and environmental exposure associated with increased lung cancer risk among workers
and residents in the vicinity of a smelter [38,39].
3. Health Effects of Arsenic Exposure
Acute arsenic poisoning is associated initially with nausea, vomiting, abdominal pain, and
severe diarrhea [40]. Encephalopathy and peripheral neuropathy may occur. Paresthesia in the
limbs is a frequent symptom of iAs exposure, which in some cases may develop into widespread
polyneuropathy [41].
Prolonged iAs exposure affects the skin, particularly with localization at skin folds. This can give
rise to changes in pigmentation, hyperkeratosis and over time, development of skin cancer, e.g., in the
hands. Upon such exposure As is a well-documented human carcinogen affecting numerous organs [5].
Significantly increased risks of lung, urinary tract as well as skin cancer are reported at levels in
drinking water around and above 50 µg/L [42]. Analyses of exposure to (As) in many epidemiological
studies suggest that there might be a small elevation of the risk to develop bladder cancer when the As
levels in drinking water are as low as 10 µg/L [43], although a recent meta-analysis revealed no increase
in risk at this level [44]. JECFA noted, however, that in epidemiological studies in that low dose-range
the risk probably would be too low to be detected, due to interferences from confounding factors like
cigarette smoking. In Northern Chile, as in Southeast Asian districts, epidemiological evidence has
shown a dose-dependent association between chronic As exposure and the different cancer forms [45],
An increased risk of bladder as well as lung cancer persisted for at least three decades after a high
exposure had ended [46].
Other sensitive endpoints of prolonged exposure are peripheral neuropathy, cardiovascular
disease, and in exposed children neurobehavioral effects [47]. Some research suggests that exposure
to environmental As might be a risk factor in children for the development of autism spectrum
disorder. However, these findings are inconclusive [48,49]. In experimental studies exposure to
As disturbs the neurotransmitter metabolism. Arsenic disrupts the glutamate-induced release of
gliotransmitters, causing changes in the neuronal function [50]. In addition, iAs exposure may
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impair the transport of glutamate [51]. In rats, iAs exposure significantly impacted brain cholinergic
receptors [52]. Furthermore, in cells, the interplay between dopamine and iAs increased the neurotoxic
effects on the dopaminergic neurons [53].
Arsenic exposure can also precipitate type 2 diabetes mellitus in susceptible cases [54]. Long-term
iAs exposure induces increased oxidative stress, which may explain deteriorations in structures and
functions of the cardiovascular system. Furthermore, by increasing the tendency of platelet aggregation,
As can aggravate atherosclerosis. Endothelial nitric oxide synthase is inactivated by As, which causes
reduced nitric oxide production in the vascular bed [55]. Arsenic exposures may also upregulate the
expression of interleukin-1, tumor necrosis factor-α, vascular endothelial growth factor, and vascular
cell adhesion molecule, and thereby causing endothelial dysfunction and aggravating cardiovascular
pathology [56]. Furthermore, epidemiological observation studies in humans showed an association
between As exposure and impaired reproductive function in males [57].
4. The Metabolism and Mechanisms of Toxicity
Arsenic undergoes in vivo several complex metabolic conversions. Both As and its metabolites
interact with extra- and intracellular macromolecules, in particular, those containing vicinal thiols, but
the mechanism of action might vary with respect to chemical form of As [7,58]. Methylation of iAs
has been considered as a part of a detoxification pathway for many years. However, newer research
indicates that intermediary metabolites, in particular, monomethylarsonous acid (MMA-III), but also
dimethylarsonous acid (DMA-III), are reactive and toxic [59]. Although MMA-III and DMA-III are
usually quickly oxidized to the less toxic pentavalent species, the intermediates in the iAs methylation
pathways can cause toxic effects, including DNA-damage [7]. Indeed, a higher primary iAs methylation
activity has in epidemiological studies been associated with an increased risk of skin lesions including
skin cancer [6].
Research has identified a monomethyl arsonic acid reductase (MMA-V reductase) that function as
a catalyst when As(V), DMA(V), and MMA(V) are reduced to the more toxic trivalent species [60],
presumably through reactions depending on the presence of reduced glutathione [61]. Recently, in a
study in mice, it has been found that oral DMA-V in significant amounts is reduced to DMA-III in the
intestine and liver as first-pass effects, and bonded extensively to tissues and red blood cells [62].
Both the peripheral and the central nervous systems may be affected by As neurotoxicity [63]. In
particular, As exposure significantly affects the glial component of the central nervous system [64]. The
neurotoxic effects caused by As exposure seems to be oxidative stress-mediated [65]. Mitochondria is
the major target for As neurotoxicity [66]. Arsenic inhibits the complexes I, II, and IV of the electron
transport chain, which elevate mitochondrial production of reactive oxygen species. In turn, this
mitochondrial disturbance may lead to microglial cell apoptosis [67]. Microglia is more sensitive
to As (III) toxicity than to As (V) [68]. Brain morphology in rodents may be significantly affected
by As exposure, which results in neuronal degeneration, gliosis, and disruption of the blood-brain
barrier [69]. Arsenic may impair neurite outgrowth [70]. Chronic As exposure in rats causes neuronal
apoptosis in the hippocampus, and cognitive impairments, like spatial memory impairment [71–73].
In mice exposed to As, As-induced alteration in the metabolic pathway of arachidonic acid may
be a factor in the mediation of neuronal damage and inflammatory response [74]. In astrocytes,
sub-toxic doses of monomethylarsonous acid increase the pro-inflammatory cytokines gene expression
significantly [75]. Neuronal apoptosis is induced both by dimethylarsinic acid and iAs [76]. In
particular, one class of arsenolipids, arsenohydrocarbons, is toxic to human neurons in vitro and is able
to cross an in vitro brain barrier model [77–79]. Hence, this class of compounds might have a potential
for neurodevelopmental toxicity.
The acute toxicity of As is ascribed to the strong affinity of As (III) for SH-groups. It is now well
known that endogenous thiols can be occupied by As compounds, such as in some cofactors (i.a. lipoic
acid) or cysteine residues that are essential constituents in the active sites of crucial enzymes. Thus,
early studies disclosed that As (III)-compounds block the function of the sulfur-containing pyruvate
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dehydrogenase enzyme complex, which is crucial for the conversion of pyruvate to acetyl-CoA that
enters the citric acid cycle. This vulnerable enzyme complex is essential for mitochondrial functions [80].
Experimentally, some of the mitochondrial effects appear to be reversed by administration of the
cofactor α-lipoic acid [81]. Additionally, As (V) competes with phosphate, thus further inhibiting or
blocking the mitochondrial respiration and the ATP synthesis. These metabolic interferences may lead
to death from multi-organ failure.
It has been documented that As(III)-compounds inhibit cytosolic SH-enzymes such as glutathione
reductase [82]. Other important targets are selenol groups in, e.g., the seleno-enzymes glutathione
peroxidase and thioredoxin reductase, the latter also containing a thiol group vicinal to the selenol
group [16,82]. Through these interactions, As appears to impair scavenging of intracellular hydrogen
peroxide (H2O2) production, which can react further to highly reactive and short-lived hydroxyl radicals.
Usually As-III-compounds are considered to represent the most toxic and carcinogenic species,
and mechanisms of actions including chromosomal effects are discussed in a recent review [83].
However, it should be noted that DMA-V can induce bladder cancer in rats and lung tumors in mice [6].
Research has linked long-term As exposure to epigenetic changes, which might also cause heritable
gene expression changes [84]. These changes include histone modification, RNA interference, and DNA
methylation [85]. For instance, excessive levels of As cause critical DNA hypermethylation via tumor
protein p53, which increase the carcinogenesis risk. Other important mechanisms of carcinogenicity
are inhibition of various DNA repair systems as well as interference with redox regulation and
ROS production [86–89]. The organic arsenical arsenobetaine, the dominating species in seafood, is
excreted unchanged and considered to be of low toxicity and is not classified as carcinogenic. The
possible toxicities of arsenosugars and arsenolipids are insufficiently studied, but these species may
split off DMA in the intestine [90] where, as mentioned above, it might be reduced to the bioactive
trivalent DMA-III.
5. Treatment of Arsenic Poisoning
The classic antidote against acute arsenic poisoning, BAL (British anti-Lewite,
dimercaptopropanol), was originally developed as a war gas antidote for Lewisite (dichlorovinyl
arsine). BAL is a dithiol compound, which competes successfully with endogenous SH-groups, e.g.,
with the sulfur groups of the pyruvate dehydrogenase cofactor α-lipoate for As in cases of arsenical
poisonings, thereby enhancing As elimination from the body.
However, due to the rather high toxicity of BAL, and the necessity of frequent and inconvenient
intramuscular administrations [91,92], the clinical use of this drug is currently restricted to only the
initial treatment for few days after acute As intoxications [93]. Water-soluble and less toxic derivatives
of BAL have been developed for therapeutic use, viz. DMSA (dimercaptosuccinic acid) and DMPS
(dimercaptopropane sulfonate) which was in regular clinical use in China [94] and the former Soviet
Union [95] early after 1950. Several decades had to pass after their original introduction [96,97] before
Western clinicians fully realized their value. Today, treatment of acute and also some severe cases
of chronic As poisoning makes use of DMPS as chelating antidote [98]. In acute life-threatening
poisonings, it is recommended to support vital functions and perform chelation therapy as fast as
possible. The therapy implies BAL i.m. in doses calculated as 5 mg/kg and a maximum of 300 mg
i.m. four times daily during the first days, combined with DMPS i.v. to provide a more efficient
therapeutic approach than obtained with monotherapy in the initial stage [98,99]. It is reasonable to
presume that BAL can act as a shuttling agent for intra- to the extracellular transfer of As in emergency
cases, the extracellular metal is then picked up by circulating DMPS with the formed As-DMPS-chelate
being rapidly excreted via urine. Successful treatment with DMPS has been described in different case
reports [100,101]. After the initial high-dosed therapy, the chelation regimen is usually switched to oral
monotherapy with DMPS. In acute cases of massive arsenic trioxide poisoning supplementation of the
chelator combination with gastric rinsing and forced alkaline diuresis, has been recommended [102].
If renal failure occurs, hemodialysis should be initiated and combined with chelation. The present
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recommendations have been precipitated from a recent extensive review of the available database of
case reports and animal experiments on chelation therapy in As poisonings [103].
The efficacy of DMPS in chronic As toxicity was observed in a placebo-controlled study of patients
exposed to As-contaminated drinking water. DMPS was given orally to 11 patients for three weeks
with inter-current chelator-free weeks, and ten patients received a placebo. Significant improvement in
symptoms of neuropathy and lung symptoms was found in the DMPS group compared to the placebo
group [104]. In contrast, only negligible improvement has been observed after monotherapy with
DMSA [104,105]. To the knowledge of the authors, combinations of BAL or DMPS with lipoic acid
(LA) or its reduced form (DHLA) have yet not been tried clinically in such poisonings. With regard
to the carcinogenic effect of prolonged As exposure, it has been hypothesized that an adequate or
supra-nutritional status of selenium may exert a protective action [106]. This hypothesis is supported
by some epidemiological and experimental studies [107,108], but further research is needed.
6. Chemical Features of BAL, DMSA, and DMPS and Their As(III)-Chelates
Many of the toxic compounds and metabolites of inorganic and organic arsenicals can be
described by the general formula, R-As2+, which explains that vicinal dithiols constitute particularly
vulnerable targets. Vicinal dithiols such as DHLA, BAL, DMPS, and DMSA are also the most efficient
chelating antidotes.
6.1. Protonation Constants
We report the acidic properties of the chelating agents DHLA, BAL, DMSA, and DMPS, to obtain
insight into the chemical form and behavior of the parent molecules in vivo, i.e., in blood with pH 7.4
and urine with pH usually about 6. The protonation constants are of particular importance since they
determine the biological properties of a drug, such as its solubility, absorption, cell penetration, and
bioavailability. Furthermore, protonation constants are of primary importance also in determining
the speciation of the complexes formed with trivalent arsenic. Table 1 reports selected protonation
constants of these ligands (those concerning the SH-groups are marked in red) together with their
structure, the used acronyms, the formulae, and the molecular weights. It appears that the protonation
constants (log K1) of the SH-groups of BAL, DMSA, DMPS and DHLA are in the range 10.6–12, while
log K2 is about two units lower, ranging from 8.6 to 9.9, the differences among the various ligands
depending on the charge of the molecule and on the distance between the mercapto groups.
Table 1. Protonation constants of BAL, DMSA, DMPS, lipoic acid (LA), and dihydrolipoic acid (DHLA).
Structure Name Formula MW log K1 log K2 log K3 log K4
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after monotherapy with DMSA [104,105]. To the knowledge of the authors, combinations of BAL or 
DMPS with lipoic acid (LA) or its reduced form (DHLA) have yet not been tried clinically in such 
poisonings. With regard to the carcinogenic effect of prolonged As exposure, it has been 
hypothesized that an adequate or supra-nutritional status of selenium may exert a protective action 
[106]. This hypothesis is supported by some epidemiological and experimental studies [107,108], but 
further research is needed. 
6. Chemical Features of BAL, DMSA, and DMPS and Their As(III)-Chelates 
Many of the toxic compounds and metabolites of inorganic and organic arsenicals can be 
described by the general formula, R-As2+, which explains that vicinal dithiols constitute particularly 
vulnerable targets. Vicinal dithiols such as DHLA, BAL, DMPS, and DMSA are also the most efficient 
chelating antidotes. 
6.1. Protonation Constants 
We report the acidic properties of the chelating agents DHLA, BAL, DMSA, and DMPS, to obtain 
insight into the chemical form and behavior of the parent molecules in vivo, i.e., in blood with pH 7.4 
and urine with pH usually about 6. The protonation constants are of particular importance since they 
determine the biological properties of a drug, such as i  solubility, absorption, cell penetrati n, a d 
bioavailability. Furthermore, proton tion constants are of primary imp rtance als  in determining 
the speciation of the complexes formed with trivalent arsenic. Table 1 reports selected protonation 
consta ts of these lig nds (thos  c ncerning the SH-groups are marked in red) together with their 
structure, the used acronyms, the formulae, and the molecular weights. It appears that the proto ation 
constants (log K1) of the SH-groups of BAL, DMSA, DMPS and DHLA are in the range 10.6–12, while 
log K2 i  about two u it  lower, ra ging from 8.6 to 9.9, the differences among th  va ious ligands 
depending on the charge of the molecule and on the distance between the m rcapto grou s. 
Lipoic acid is also included in Table 1 since this enzymatic cofactor is considered a primary target 
of the As (III) toxicity when the metalloid blocks the pyruvate d hydrogenase complex. 
Table 1. Protonation constants of BAL, DMSA, DMPS, lipoic acid (LA), and dihydrolipoic acid 
(DHLA). 
Structure Name Formula MW log K1 log K2 log K3 log K4 
 
BAL C3H8OS2 124.23 [109] 10.62 8.65   
 
DMSA C4H6O4S2 182.22 [110] 12.05 9.65 3.43 2.71 
 
DMPS C3H8O3S3 188.28 [109] 11.38 8.69   
 
LA C8H14O2S2 206.34 [111] 4.704    
 
DHLA C8H16O2S2 208.34 [112] 11.02 9.86 4.73  
The protonation constants related to the SH-groups are marked in red. 
C4H6O4S2 182. 2 [110] 12.05 9.65 3.43 2.71
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recent extensive review of the available database of case reports and animal experiments on chelation 
therapy in As poisonings [103]. 
The efficacy of DMPS in chronic As toxicity was observed in a placebo-controlled study of 
patients exposed to As-contaminated drinking water. DMPS was given orally to 11 patients for three 
weeks with inter-current chelator-free weeks, and ten patients received a placebo. Significant 
improvement in symptoms of neuropathy and lung symptoms was found in the DMPS group 
compared to the placebo group [104]. In contrast, only negligible improvement has been observed 
after monotherapy with DMSA [104,105]. To the knowledge of the authors, combinations of BAL or 
DMPS with lipoic acid (LA) or its reduced form (DHLA) have yet not been tried clinically in such 
poisonings. With regard to the carcinogenic effect of prolonged As exposure, it has been 
hypothesized that an adequate or supra-nutritional status of selenium may exert a protective action 
[106]. This hypothesis is supported by some epidemiological and experimental studies [107,108], but 
further research is needed. 
6. Chemical F atures of BAL, DMSA, and DMPS and Their As(III)-C lat s 
Many of the toxic compounds and metabolites of inorganic and organic arsenicals can be 
described by the general formula, R-As2+, which explains that vicinal dithiols constitute particularly 
vulnerable targets. Vicinal dithiols such as HLA, BAL, DMPS, and DMSA are also the most efficient 
chelating antidotes. 
6.1. Protonation Constants 
We report the acidic properties of the chelating agents DHLA, BAL, DMSA, and DMPS, to obtain 
insight into the chemical form and behavior of the parent molecules in vivo, i.e., in blood with pH 7.4 
and urine with pH usually about 6. The protonation constants are of particular importance since they 
determine the biological properties of a drug, such as its solubility, absorption, cell penetration, and 
bioavailability. Furthermore, protonation constants are of primary importance also in determining 
the speciation of the complexes formed with trivalent arsenic. Table 1 reports selected protonation 
constants of these ligands (those concerning the SH-groups are marked in red) together with their 
structure, the used acronyms, the formulae, and the molecular weights. It appears that the protonation 
constants (log K1) of the SH-groups of BAL, DMSA, DMPS and DHLA are in the range 10.6–12, while 
log K2 is about two units lower, ranging from 8.6 to 9.9, the differences among the various ligands 
depending on the charge of the molecule and on the distance between the mercapto groups. 
Lipoic acid is also included in Table 1 since this enzymatic cofactor is considered a primary target 
of the As (III) toxicity when the metalloid blocks the pyruvate dehydrogenase complex. 
Table 1. Protonation constants of BAL, DMSA, DMPS, lipoic acid (LA), and dihydrolipoic acid 
(DHLA). 
Structure Name Formula MW log K1 log K2 log K3 log K4 
 
BAL C3H8OS2 124.23 [109] 10.62 8.65   
 
DMSA C4H6O4S2 182.22 [110] 12.05 9.65 3.43 2.71 
 
DMPS C3H8O3S3 188.28 [109] 11.38 8.69   
 
LA C8H14O2S2 206.34 [111] 4.704    
 
DHLA C8H16O2S2 208.34 [112] 11.02 9.86 4.73  
The protonation constants related to the SH-groups are marked in red. 
C8H16 2 2 208.34 [112] 11.02 9.86 4.73
The protonation c ts related to the SH-groups are marked in red.
Lipoic acid is also included in Table 1 since this enzymatic cofactor is considered a primary target
of the As (III) toxicity when the metalloid blocks the pyruvate dehydrogenase complex.
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6.2. Chemical Stabilities of the As-Chelates
Available literature reports only few stoichiometric data on the complex formation equilibria
between the thiol chelating agents and As (III) compounds. However, a number of papers describe the
principal features of complexes studied with different techniques, briefly summarized in the following.
A paper by Dill et al. [113] reports one- and two-dimensional (homonuclear and heteronuclear)
NMR studies on BAL and its phenyldichloroarsine (PDA) adduct, where PDA is a Lewisite analog
(Figure 2). PDA appears to react with BAL such that in the complex, the hydroxymethyl group is
anti to the phenyl ring, and to a less extent a syn structure was observed. A successive paper by the
same authors [114] took into consideration the structures of DMSA and DMPS adducts with PDA, and
Lewisite (trans-2-chlorovinylarsine) oxide (LO) (Figure 2).
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The 1:1 adducts were synthesized and characterized by one- and two-dimensional NMR 
spectroscopy. All the formed complexes were five-membered heteroatomic ring systems (chelates), 
with different solubility properties (Figure S1). The results indicated that the functional groups of the 
chelating agent influenced stereochemical aspects of adduct formation [114]. 
Adams et al. presented an X-Ray and spectroscopic investigation on the interaction of several 
arylarsenic dichlorides with BAL and DMSA [115]. In the single crystal of the complex between 
CH3C6H4AsCl2 and BAL the arsenic was found in a distorted-square-pyramidal coordination 
geometry (Table S1), with one of the sulfur atoms on each of the chelating ligands considerably 
further away from the arsenic than the other. The five-membered ring presents with an envelope 
configuration where the hydroxymethyl group is located on a hinge of the envelope anti to the phenyl 
group of the arsenic. Although no single crystals of the DMSA adducts were suitable for X-ray 
diffraction, the IR spectra of the complexes clearly showed both the OH groups of the ligand as well 
as its C=O stretch, and the stretches due to substituted phenyl groups. The 13C NMR spectrum was 
also highly indicative of arsenic coordination. 
Fairlamb et al. [116] report that D,L-dihydrolipoamide and DHLA form stable complexes with 
melarsen oxide (Figure 3) with complex formation constants of 5.47 × 109 and 4.51 × 109 M−1, 
respectively. 
 
Figure 3. Chemical formulae of melarsen oxide. 
These complexes, characterized by six-membered cyclic dithioarsenite rings, are 10-fold less 
stable than the complexes with five-membered rings found with BAL (79.30 × 109 M−1) and DMSA 
Figure 2. Chemical formulae of phenyldichloroarsine (PDA) and Lewisite oxide (LO).
The 1:1 adducts were synthesized and characterized by one- and two-dimensional NMR
spectroscopy. All the formed complexes were five-membered heteroatomic ring systems (chelates),
with different solubility properties (Figure S1). The results indicated that the functional groups of the
chelating agent influenced stereochemical aspects of adduct formation [114].
Adams et al. presented an X-Ray and spectroscopic investigation on the interaction of several
arylarsenic dichlorides with BAL and DMSA [115]. In the single crystal of the complex between
CH3C6H4AsCl2 and BAL the arsenic was found in a distorted-square-pyramidal coordination geometry
(Table S1), with one of the sulfur atoms on each of the chelating ligands considerably further away
from the arsenic than the other. The five-membered ring presents with an envelope configuration where
the hydroxymethyl group is located on a hinge of the envelope anti to the phenyl group of the arsenic.
Although no single crystals of the DMSA adducts were suitable for X-ray diffraction, the IR spectra of
the complexes clearly showed both the OH groups of the ligand as well as its C=O stretch, and the
stretches due to substituted phenyl groups. The 13C NMR spectrum was also highly indicative of
arsenic coordination.
Fairlamb et al. [116] report that D,L-dihydrolipoamide and DHLA form stable complexes
with melarsen oxide (Figure 3) with complex formation constants of 5.47 × 109 and 4.51 × 109
M−1, respectively.
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These complexes, characterized by six-membered cyclic dithioarsenite rings, are 10-fold less
stable than the complexes with five-membered rings found with BAL (79.30 × 109 M−1) and DMSA
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(45.00 × 109 M−1) by Fairlamb et al. [117]. The solid-state structure of the complex between PhAs (III)
and DHLA shown in Figure 4, was reported by von Döllen and Strasdeit [118].
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Cambridge Structural Database (NIDKAM), and the image was created using Mercury3.5. 
Spuches et al. [119] used near-UV absorption spectroscopy and isothermal titration calorimetry 
to quantify the stability and thermodynamics of formation of arsenite and monomethylarsenite 
(MMA) complexes with DMSA, dithiothreitol (DTT), and DHLA. They found that MMA forms 
chelates with the dithiols somewhat more stable than those of arsenite. 
Cavanillas et al. [120] made use of a new methodology that combines voltammetry, ITC, ESI-
MS, and several chemometric tools to the study of As(III) complexes with DMSA and DMPS, 
obtaining estimates of the stoichiometries of the complexes formed (ML2, with the appearance of only 
minor amounts of ML-species), and approximately similar As(III)-complex formation constants for 
the two agents (log β2 9.2 and 9.8 for DMSA and DMPS, respectively). 
Harper and Bayse [121] used density functional theory (DFT) and solvent-assisted proton 
exchange (SAPE) to model the chelation of the As in Lewisite by the vicinal thiols of BAL. They 
concluded, “the low barriers for lewisite detoxification by BAL and the greater stability of the 
chelation complexes of small dithiols are consistent with the rapid reversal of toxicity demonstrated 
in previously reported animal models”. 
7. Discussion and Conclusions 
Humans are exposed to As compounds from many sources, including occupational and 
environmental sources, which include drinking water and food items. Exposure may range from 
acutely toxic to various levels of long-term or life-long exposure. High As levels in food or drinking 
water, or under some occupational conditions, can in some cases precipitate chronic poisoning and 
in some cases cancer. Individuals subjected to high or long-term exposure may develop acute, 
subacute, or chronic signs of poisoning, characterized by skin lesions, cardiovascular diseases, and/or 
neurological symptoms. Pentavalent organic As found in marine species appears to be less toxic than 
trivalent inorganic and methylated species. 
The reviewed analytical results support the hypotheses that the endogenous vicinal dithiol 
DHLA, and the therapeutic agents BAL and DMPS, have a particularly high affinity for arsenical 
compounds. The relative affinity of selenol groups for arsenicals may be even higher, but 
determinations of the chemical stabilities of these chelates are sparse or missing. 
Apparently, both inorganic arsenite (III) and R-As2+-compounds are bound tightly to thiol 
groups, which constitute vulnerable targets for the toxic action of As. Selenol groups, e.g., in seleno-
enzymes and particularly in conjunction with thiol groups as in thioredoxin reductase, are 
anticipated to have an even higher affinity to R-As2+-compounds, explaining the oxidative stress 
associated with arsenic toxicity. The strong general affinity to thiols and selenols may explain the 
many targets of arsenicals and a wide range of adverse health effects. Among therapeutic agents, the 
Figure 4. Structures of phenylarsenic with DHLA, where hydrogen is shown in light grey, carbon in
grey, sulfur in yellow, oxygen in red, and As (III) in violet. The coordinates were obtained from the
Cambridge Structural Database (NIDKAM), and the image was created using Mercury3.5.
Spuches et al. [119] used near-UV absorption spectroscopy and isothermal titration calorimetry to
quantify the stability and thermodynamics of formation of arsenite and monomethylarsenite (MMA)
complexes with DMSA, dithiothreitol (DTT), and DHLA. They found that MMA forms chelates with
the dithiols somewhat more stable than those of arsenite.
Cavanillas et al. [120] made use of a new methodology that combines voltammetry, ITC, ESI-MS,
and several chemometric tools to the study of As(III) complexes with DMSA and DMPS, obtaining
estimates of the stoichio etries of the complexes formed (ML2, with the appearance of only minor
amounts of ML-species), and approximately similar As(III)-co plex formation constants for the two
agents (log β2 9.2 and 9.8 for DMSA and DMPS, respectively).
Harper and Bayse [121] used density functional theory (DFT) and solvent-assisted proton exchange
(SAPE) to model the chelation of the As in Lewisite by the vicinal thiols of BAL. They concluded, “the
low barriers for lewisite detoxification by BAL and the greater stability of the chelation complexes of
small dithiols are consistent with the rapid reversal of toxicity demonstrated in previously reported
animal models”.
7. Discussion and Conclusions
Humans are exposed to As compounds from many sources, including occupational and
environ ental sources, which include drinking water and food items. Exposure may range from
acutely toxic to variou levels of long-term or life-long exposure. High As levels in food or drinking
water, or under some occupational conditions, can in some cases precipitate chron c p isoning a d in
som cases cancer. Individ als subjected to high or long-ter exposure may develop acute, subacute, or
chronic sign of poisoning, characterized by skin les ons, cardiovascular diseas s, and/or n urological
ymptoms. Pentavalent organic As found in marine species appears to be le s toxic th n trivalent
i organic and methylated species.
The reviewed analytical results upport the hypotheses that the endogenous vicinal dithiol DHLA,
and the therapeutic agents BAL and DMPS, have a particularly high affinity f r arsenical ompounds.
The relative affinity of selenol groups for arsenicals may be even higher, but determinations of the
hemical stabiliti s of thes chelates are sparse or missing.
App rently, both inorganic arsenite (III) and R-As2+-compound are bound tightly to thiol groups,
which constitute vulnerable t rgets for th toxic ction of As. Selenol groups, e.g., in seleno-enzymes
and particularly i conjunction with thiol groups as in thioredoxin reductase, are anticipated to have
a even higher affin ty to R-As2+-compounds, explaining the oxid tive stress ass c ated with arsenic
toxicity. The strong ge eral affinity to th ols and selenols ay explain the ma y argets of arsenicals
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and a wide range of adverse health effects. Among therapeutic agents, the most efficient chelators are
the dithiols BAL and DMPS, both of which with particularly high affinity to R-As2+-compound.
Whereas primary prevention aiming to reduce environmental exposure to toxic inorganic As and
organic As from drinking water and food for the many millions of people with unacceptable exposure
to As should be the prioritized approach, therapeutic intervention may be needed in cases of acute,
subacute, and even chronic As poisonings. Here chelation with DMPS, which can be administered
orally or intravenously, appears promising as regards alleviation of symptoms. In severe acute cases,
a combination of DMPS intravenously with BAL intramuscularly can be used in the first days of
the treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/2/235/s1,
Figure S1. Molecular formulae of the 1:1 adducts proposed in reference [114] based on NMR results formed
between A) trans-2-chlorovinylarsine oxide or lewisite oxide (LO) and DHLA; B) LO and DMSA; C) LO and
DMPS; D) PDA and DMSA; E) PDA and DMPS, Table S1. Structures of As(III) with different ligands bearing
mercapto groups, where hydrogen is shown in light grey, carbon in grey, nitrogen in blue, sulfur in yellow, oxygen
in red, and As(III) in violet. The coordinates were obtained from the Cambridge Structural Database, and the
image was created using Mercury3.5.
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57. Lovaković, B.T. Cadmium, arsenic and lead—Elements affecting male reproductive health. Curr. Opin.
Toxicol. 2019.
Biomolecules 2020, 10, 235 13 of 16
58. Naranmandura, H.; Xu, S.; Sawata, T.; Hao, W.H.; Liu, H.; Bu, N.; Ogra, Y.; Lou, Y.J.; Suzuki, N. Mitochondria
are the main target organelle for trivalent monomethylarsonous acid (MMA(III))-induced cytotoxicity.
Chem. Res. Toxicol. 2011, 24, 1094–1103. [CrossRef]
59. Bozack, A.K.; Saxena, R.; Gamble, M.V. Nutritional Influences on One-Carbon Metabolism: Effects on Arsenic
Methylation and Toxicity. Annu. Rev. Nutr. 2018, 38, 401–429. [CrossRef]
60. Zakharyan, R.A.; Tsaprailis, G.; Chowdhury, U.K.; Hernandez, A.; Aposhian, H.V. Interactions of sodium
selenite, glutathione, arsenic species, and omega class human glutathione transferase. Chem. Res. Toxicol.
2005, 18, 1287–1295. [CrossRef]
61. Németi, B.; Gregus, Z. Reduction of arsenate to arsenite by human erythrocyte lysate and rat liver
cytosol—Characterization of a glutathione—And NAD-dependent arsenate reduction linked to glycolysis.
Toxicol. Sci. 2005, 85, 847–858. [CrossRef]
62. Twaddle, N.C.; Vanlandingham, M.; Beland, F.A.; Doerge, D.R. Metabolism and disposition of arsenic species
from controlled dosing with dimethylarsinic acid (DMAV) in adult female CD-1 mice. V. Toxicokinetic
studies following oral and intravenous administration. Food Chem. Toxicol. 2019, 130, 22–31. [CrossRef]
63. Frankel, S.; Concannon, J.; Brusky, K.; Pietrowicz, E.; Giorgianni, S.; Thompson, W.D.; Currie, D.A. Arsenic
exposure disrupts neurite growth and complexity in vitro. Neurotoxicology 2009, 30, 529–537. [CrossRef]
64. Chen, G.; Mao, J.; Zhao, J.; Zhang, Y.; Li, T.; Wang, C.; Xu, L.; Hu, Q.; Wang, X.; Jiang, S.; et al. Arsenic
trioxide mediates HAPI microglia inflammatory response and the secretion of inflammatory cytokine IL-6
via Akt/NF-κB signaling pathway. Regul. Toxicol. Pharmacol. 2016, 81, 480–488. [CrossRef] [PubMed]
65. Liu, X.; Gao, Y.; Yao, H.; Zhou, L.; Sun, D.; Wang, J. Neuroglobin involvement in the course of arsenic toxicity
in rat cerebellar granule neurons. Biol. Trace Elem. Res. 2013, 155, 439–446. [CrossRef] [PubMed]
66. Prakash, C.; Soni, M.; Kumar, V. Mitochondrial oxidative stress and dysfunction in arsenic neurotoxicity: A
review. J. Appl. Toxicol. 2016, 36, 179–188. [CrossRef]
67. Kharroubi, W.; Haj Ahmed, S.; Nury, T.; Andreoletti, P.; Sakly, R.; Hammami, M.; Lizard, G. Mitochondrial
dysfunction, oxidative stress and apoptotic induction in microglial BV-2 cells treated with sodium arsenate.
J. Environ. Sci. 2017, 51, 44–51. [CrossRef] [PubMed]
68. Wu, T.J.; Weng, S.T.; Tzeng, S.F. Effect of arsenite and arsenate on microglial cell survival. In Arsenic in
Geosphere and Human Diseases Arsenic 2010, Proceedings of the Third International Congress on Arsenic in the
Environment (As-2010); CRC Press: London, UK, 2010; ISBN 9780415578981.
69. Selim, S.A.; Selim, A.O.; Askar, E.M. Harmful effects of arsenic on the cerebral cortex of adult male albino
rats: Light and electron microscopic studies. Egyptian J. Histol. 2012, 35, 249–258. [CrossRef]
70. Wang, X.; Meng, D.; Chang, Q.; Pan, J.; Zhang, Z.; Chen, G.; Ke, Z.; Luo, J.; Shi, X. Arsenic Inhibits Neurite
Outgrowth by Inhibiting the LKB1–AMPK Signaling Pathway. Environ. Health Perspect. 2010, 118, 627–634.
[CrossRef]
71. Pandey, R.; Rai, V.; Mishra, J.; Mandrah, K.; Kumar Roy, S.; Bandyopadhyay, S. From the Cover:
Arsenic Induces Hippocampal Neuronal Apoptosis and Cognitive Impairments via an Up-Regulated
BMP2/Smad-Dependent Reduced BDNF/TrkB Signaling in Rats. Toxicol. Sci. 2017, 159, 137–158. [CrossRef]
72. Chandravanshi, L.P.; Shukla, R.K.; Sultana, S.; Pant, A.B.; Khanna, V.K. Early life arsenic exposure and brain
dopaminergic alterations in rats. Int. J. Dev. Neurosci. 2014, 38, 91–104. [CrossRef]
73. Ramos-Chávez, L.A.; Rendón-López, C.R.R.; Zepeda, A.; Silva-Adaya, D.; Del Razo, L.M.; Gonsebatt, M.E.
Neurological effects of inorganic arsenic exposure: Altered cysteine/glutamate transport, NMDA expression
and spatial memory impairment. Front. Cell Neurosci. 2015, 9, 21. [CrossRef]
74. Anwar-Mohamed, A.; Elshenawy, O.H.; El-Sherbeni, A.A.; Abdelrady, M.; El-Kadi, A.O.S. Acute arsenic
treatment alters arachidonic acid and its associated metabolite levels in the brain of C57Bl/6 mice. Can. J.
Physiol. Pharmacol. 2014, 92, 693–702. [CrossRef]
75. Escudero-Lourdes, C.; Uresti-Rivera, E.E.; Oliva-González, C.; Torres-Ramos, M.A.; Aguirre-Bañuelos, P.;
Gandolfi, A.J. Erratum to: Cortical Astrocytes Acutely Exposed to the Monomethylarsonous Acid (MMAIII)
Show Increased Pro-inflammatory Cytokines Gene Expression that is Consistent with APP and BACE-1
Over-expression. Neurochem. Res. 2016, 41, 2573. [CrossRef] [PubMed]
76. Namgung, U.; Xia, Z. Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38
MAP kinases. Toxicol. Appl. Pharmacol. 2001, 174, 130–138. [CrossRef] [PubMed]
Biomolecules 2020, 10, 235 14 of 16
77. Witt, B.; Ebert, F.; Meyer, S.; Francesconi, K.A.; Schwerdtle, T. Assessing neurodevelopmental effects of
arsenolipids in pre-differentiated human neurons. Mol. Nutr. Food Res. 2017, 61, 1700199. [CrossRef]
[PubMed]
78. Witt, B.; Meyer, S.; Ebert, F.; Francesconi, K.A.; Schwerdtle, T. Toxicity of two classes of arsenolipids and their
water-soluble metabolites in human differentiated neurons. Arch. Toxicol. 2017, 91, 3121–3134. [CrossRef]
79. Müller, S.M.; Ebert, F.; Raber, G.; Meyer, S.; Bornhorst, J.; Hüwel, S.; Galla, H.-J.; Francesconi, K.A.;
Schwerdtle, T. Effects of arsenolipids on in vitro blood-brain barrier model. Arch. Toxicol. 2018, 92, 823–832.
[CrossRef]
80. Peters, R.A.; Stocken, L.A.; Thompson, R.H.S. British Anti-Lewisite (BAL). Nature 1945, 156, 616–619.
[CrossRef]
81. Shila, S.; Subathra, M.; Devi, M.A.; Panneerselvam, C. Arsenic intoxication-induced reduction of glutathione
level and of the activity of related enzymes in rat brain regions: Reversal by DL-alpha-lipoic acid. Arch. Toxicol.
2005, 79, 140–146. [CrossRef]
82. Rodríguez, V.M.; Del Razo, L.M.; Limón-Pacheco, J.H.; Giordano, M.; Sánchez-Peña, L.C.; Uribe-Querol, E.;
Gutiérrez-Ospina, G.; Gonsebatt, M.E. Glutathione reductase inhibition and methylated arsenic distribution
in Cd1 mice brain and liver. Toxicol. Sci. 2005, 84, 157–166. [CrossRef]
83. Nordberg, G.F.; Fowler, B.A.; Nordberg, M. Handbook on the Toxicology of Metals; Elsevier: London, UK, 2014;
pp. 581–624.
84. Zhou, Q.; Xi, S. A review on arsenic carcinogenesis: Epidemiology, metabolism, genotoxicity and epigenetic
changes. Regul. Toxicol. Pharmacol. 2018, 99, 78–88. [CrossRef]
85. Bjørklund, G.; Aaseth, J.; Chirumbolo, S.; Urbina, M.A.; Uddin, R. Effects of arsenic toxicity beyond epigenetic
modifications. Environ. Geochem. Health 2018, 40, 955–965. [CrossRef]
86. Ebert, F.; Weiss, A.; Bültemeyer, M.; Hamann, I.; Hartwig, A.; Schwerdtle, T. Arsenicals affect base excision
repair by several mechanisms. Mutat. Res.-Fund. Mol. M 2011, 715, 32–41. [CrossRef]
87. Holcomb, N.; Goswami, M.; Han, S.G.; Scott, T.; D’Orazio, J.; Orren, D.K.; Gairola, C.G.; Mellon, I. Inorganic
arsenic inhibits the nucleotide excision repair pathway and reduces the expression of XPC. DNA Repair 2017,
52, 70–80. [CrossRef] [PubMed]
88. Hartwig, A. Metal interaction with redox regulation: An integrating concept in metal carcinogenesis? Free
Rad. Biol. Med. 2013, 55, 63–72. [CrossRef] [PubMed]
89. Nollen, M.; Ebert, F.; Moser, J.; Mullenders, L.H.F.; Hartwig, A.; Schwerdtle, T. Impact of arsenic on nucleotide
excision repair: XPC function, protein level, and gene expression. Mol. Nutr. Food Res. 2009, 53, 572–582.
[CrossRef] [PubMed]
90. Taylor, V.F.; Li, Z.; Sayarath, V.; Palys, T.J.; Morse, K.R.; Scholz-Bright, R.A.; Karagas, M.R. Distinct arsenic
metabolites following seaweed consumption in humans. Sci. Rep. 2017, 7. [CrossRef] [PubMed]
91. Aaseth, J. Recent advance in the therapy of metal poisonings with chelating agents. Hum. Toxicol. 1983, 2,
257–272. [CrossRef] [PubMed]
92. Bjørklund, G.; Mutter, J.; Aaseth, J. Metal chelators and neurotoxicity: Lead, mercury, and arsenic. Arch. Toxicol.
2017, 91, 3787–3797. [CrossRef]
93. Andersen, O.; Aaseth, J. Molecular mechanisms of in vivo metal chelation: Implications for clinical treatment
of metal intoxications. Environ. Health Perspect. 2002, 110 (Suppl. 5), 887–890. [CrossRef]
94. Ding, G.S.; Liang, Y.Y. Antidotal effects of dimercaptosuccinic acid. J. Appl. Toxicol. 1991, 11, 7–14. [CrossRef]
95. Oginski, M. Use of Unitiol for speeding up renal excretion of chlormerodrin 203 Hg. Int. Urol. Nephrol. 1971,
3, 203–208. [CrossRef]
96. Friedheim, E.A.; Da Silva, J.R.; Martins, A.V. Treatment of schistosomiasis mansoni with antimony-omega,
omega-dimercapto-potassium succinate (TWSb). Am. J. Trop. Med. Hyg. 1954, 3, 714–727. [CrossRef]
[PubMed]
97. Aaseth, J.; Frieheim, E.A. Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid
and other complexing thiols. Acta Pharmacol. Toxicol. (Copenh) 1978, 42, 248–252. [CrossRef] [PubMed]
98. Gerhardsson, L.; Aaseth, J. Guidance for clinical treatment of metal poisonings—Use and misuse of chelating
agents. In Chelation Therapy in Treatment of Metal Intoxication; Aaseth, J., Crisponi, G., Andersen, O., Eds.;
Elsevier: London, UK, 2016; pp. 313–341.
99. Aaseth, J.; Ajsuvakova, O.P.; Skalny, A.V.; Skalnaya, M.G.; Tinkov, A.A. Chelator combination as therapeutic
strategy in mercury and lead poisonings. Coord. Chem. Rev. 2018, 358, 1–12. [CrossRef]
Biomolecules 2020, 10, 235 15 of 16
100. Moore, D.F.; O’Callaghan, C.A.; Berlyne, G.; Ogg, C.S.; Davies, H.A.; House, I.M.; Henry, J.A. Acute arsenic
poisoning: Absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS).
J. Neurol. Neurosurg. Psychiatry 1994, 57, 1133–1135. [CrossRef]
101. Wax, P.M.; Thornton, C.A. Recovery from severe arsenic-induced peripheral neuropathy with
2,3-dimercapto-1-propanesulphonic acid. J. Toxicol. Clin. Toxicol. 2000, 38, 777–780. [CrossRef]
102. Vantroyen, B.; Heilier, J.F.; Meulemans, A.; Michels, A.; Buchet, J.P.; Vanderschueren, S.; Haufroid, V.;
Sabbe, M. Survival after a lethal dose of arsenic trioxide. J. Toxicol. Clin. Toxicol. 2004, 42, 889–895. [CrossRef]
103. Aaseth, J.; Crisponi, G.; Anderson, O. Chelation Therapy in the Treatment of Metal Intoxication; Elsevier: London,
UK, 2016; pp. 85–252.
104. Guha Mazumder, D.N.; De, B.K.; Santra, A.; Ghosh, N.; Das, S.; Lahiri, S.; Das, T. Randomized
placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due
to drinking arsenic-contaminated water. J. Toxicol. Clin. Toxicol. 2001, 39, 665–674. [CrossRef]
105. Stenehjem, A.-E.; Vahter, M.; Nermell, B.; Aasen, J.; Lierhagen, S.; Mørland, J.; Jacobsen, D. Slow recovery from
severe inorganic arsenic poisoning despite treatment with DMSA (2.3-dimercaptosuccinic acid). Clin. Toxicol.
2007, 45, 424–428. [CrossRef]
106. Spallholz, J.; Malloryboylan, L.; Rhaman, M. Environmental hypothesis: Is poor dietary selenium intake an
underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India? Sci. Tot. Environ. 2004,
323, 21–32. [CrossRef]
107. Chen, Y.; Hall, M.; Graziano, J.H.; Slavkovich, V.; van Geen, A.; Parvez, F.; Ahsan, H. A Prospective Study
of Blood Selenium Levels and the Risk of Arsenic-Related Premalignant Skin Lesions. Cancer Epidemiol.
Biomarkers Prev. 2007, 16, 207–213. [CrossRef]
108. Zeng, H.; Uthus, E.O.; Combs, G.F., Jr. Mechanistic aspects of the interaction between selenium and arsenic.
J. Inorg. Biochem. 2005, 99, 1269–1274. [CrossRef] [PubMed]
109. Arnold, A.P.; Canty, A.J.; Reid, R.S.; Rabenstein, D.L. Nuclear magnetic resonance and potentiometric studies
of the complexation of methylmercury(II) by dithiols. Can. J. Chem. 1985, 63, 2430–2436. [CrossRef]
110. Carla Aragoni, M.; Arca, M.; Crisponi, G.; Cristiani, F.; Isaia, F.; Nurchi, V.M. Characterization of the ionization
and spectral properties of mercapto-carboxylic acids Correlation with substituents and structural features.
Talanta 1996, 43, 1357–1366. [CrossRef]
111. Bjørklund, G.; Crisponi, G.; Nurchi, V.M.; Cappai, R.; Buha Djordjevic, A.; Aaseth, J. A Review on Coordination
Properties of Thiol-Containing Chelating Agents Towards Mercury, Cadmium, and Lead. Molecules 2019,
24, 3247. [CrossRef]
112. Bonomi, F.; Pagani, S.; Cariati, F.; Pozzi, A.; Crisponi, G.; Cristiani, F.; Diaz, A.; Zanoni, R. Synthesis and
characterization of metal derivatives of dihydrolipoic acid and dihydrolipoamide. Inorganica Chim. Acta
1992, 192, 237–242. [CrossRef]
113. Dill, K.; Hu, S.; O’Connor, R.J.; McGown, E.L. Preparation, structure, and solution dynamics of
phenyldichloroarsine-thio sugar adducts. Carbohydr. Res. 1990, 196, 141–146. [CrossRef]
114. O’Connor, R.J.; McGown, E.L.; Dill, K.; Hallowell, S.F. Two-dimensional NMR studies of arsenical-sulfhydryl
adducts. Magn. Reson. Chem. 1989, 27, 669–675. [CrossRef]
115. Adams, E.; Jeter, D.; Cordes, A.W.; Kolis, J.W. Chemistry of organometalloid complexes with potential
antidotes: Structure of an organoarsenic(III) dithiolate ring. Inorg. Chem. 1990, 29, 1500–1503. [CrossRef]
116. Fairlamb, A.H.; Carter, N.S.; Cunningham, M.; Smith, K. Characterisation of melarsen-resistant
Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism.
Mol. Biochem. Parasit. 1992, 53, 213–222. [CrossRef]
117. Fairlamb, A.H.; Henderson, G.B.; Cerami, A. Trypanothione is the primary target for arsenical drugs against
African trypanosomes. Proc. Natl. Acad. Sci. USA 1989, 86, 2607–2611. [CrossRef]
118. Von Döllen, A.; Strasdeit, H. Models for the Inhibition of Dithiol-Containing Enzymes by Organoarsenic
Compounds: Synthetic Routes and the Structure of [PhAs(HlipS2)] (HlipS22− = Reduced Lipoic Acid). Eur. J.
Inorg. Chem. 1998, 1998, 61–66. [CrossRef]
119. Spuches, A.M.; Kruszyna, H.G.; Rich, A.M.; Wilcox, D.E. Thermodynamics of the As(III)−Thiol Interaction:
Arsenite and Monomethylarsenite Complexes with Glutathione, Dihydrolipoic Acid, and Other Thiol
Ligands. Inorg. Chem. 2005, 44, 2964–2972. [CrossRef] [PubMed]
Biomolecules 2020, 10, 235 16 of 16
120. Cavanillas, S.; Chekmeneva, E.; Ariño, C.; Díaz-Cruz, J.M.; Esteban, M. Electroanalytical
and isothermal calorimetric study of As(III) complexation by the metal poisoning remediators,
2,3-dimercapto-1-propanesulfonate and meso-2,3-dimercaptosuccinic acid. Anal. Chim. Acta 2012, 746, 47–52.
[CrossRef] [PubMed]
121. Harper, L.K.; Bayse, C.A. Modeling the chelation of As(III) in lewisite by dithiols using density functional
theory and solvent-assisted proton exchange. J. Inorg. Biochem. 2015, 153, 60–67. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
